Long-term outcome of kidney transplantation in patients with fibrillary glomerulonephritis or monoclonal gammopathy with fibrillary deposits

Peter G. Czarnecki, Donna J. Lager, Nelson Leung, Angela Dispenzieri, Fernando G Cosio, Fernando Custodio Fervenza

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

To determine the outcome of kidney transplantation in patients with fibrillary glomerulonephritis (FGN), a rare glomerular disease, we followed 12 patients, 5 with FGN and 7 patients with monoclonal gammopathy and fibrillary deposits (MGFD), who underwent 15 kidney transplants since 1988 with a median follow-up of 52 months. Recurrent disease did not arise in any of the patients with FGN but developed in 5 patients with MGFD. Seven allografts failed: 1 in the FGN group and 6 in the MGFD group. Median allograft survival for patients with MGFD was 37 months but had not been reached in FGN patients. One patient with FGN had primary allograft failure secondary to graft thromboembolism. Three patients with MGFD were re-transplanted and one lost the second allograft to recurrent disease, but the other two died from hematological malignancy. Another patient was diagnosed with MPGN type III and did not have detectable fibrillary material 22 months after transplantation. One patient with MGFD had stable allograft function 6 months post-transplant but another, with recurrent disease, underwent peripheral blood stem cell transplantation and regained stable allograft function. Our study shows that kidney transplantation appears safe in patients with FGN with little risk of recurrence. However, patients with MGFD have a significant risk for disease recurrence. Whether the development of hematological malignancies following transplantation in this group is related to their original disease or was coincidental requires further studies.

Original languageEnglish (US)
Pages (from-to)420-427
Number of pages8
JournalKidney International
Volume75
Issue number4
DOIs
StatePublished - Feb 2009

Fingerprint

Paraproteinemias
Glomerulonephritis
Kidney Transplantation
Allografts
Hematologic Neoplasms
Transplants
Transplantation
Membranoproliferative Glomerulonephritis
Peripheral Blood Stem Cell Transplantation
Recurrence
Thromboembolism
Rare Diseases

Keywords

  • Fibrillary
  • Gammopathy
  • Glomerulonephritis
  • Kidney
  • Monoclonal
  • Transplantation

ASJC Scopus subject areas

  • Nephrology

Cite this

Long-term outcome of kidney transplantation in patients with fibrillary glomerulonephritis or monoclonal gammopathy with fibrillary deposits. / Czarnecki, Peter G.; Lager, Donna J.; Leung, Nelson; Dispenzieri, Angela; Cosio, Fernando G; Fervenza, Fernando Custodio.

In: Kidney International, Vol. 75, No. 4, 02.2009, p. 420-427.

Research output: Contribution to journalArticle

@article{6e8e087dea28499a9551c12c95c93f53,
title = "Long-term outcome of kidney transplantation in patients with fibrillary glomerulonephritis or monoclonal gammopathy with fibrillary deposits",
abstract = "To determine the outcome of kidney transplantation in patients with fibrillary glomerulonephritis (FGN), a rare glomerular disease, we followed 12 patients, 5 with FGN and 7 patients with monoclonal gammopathy and fibrillary deposits (MGFD), who underwent 15 kidney transplants since 1988 with a median follow-up of 52 months. Recurrent disease did not arise in any of the patients with FGN but developed in 5 patients with MGFD. Seven allografts failed: 1 in the FGN group and 6 in the MGFD group. Median allograft survival for patients with MGFD was 37 months but had not been reached in FGN patients. One patient with FGN had primary allograft failure secondary to graft thromboembolism. Three patients with MGFD were re-transplanted and one lost the second allograft to recurrent disease, but the other two died from hematological malignancy. Another patient was diagnosed with MPGN type III and did not have detectable fibrillary material 22 months after transplantation. One patient with MGFD had stable allograft function 6 months post-transplant but another, with recurrent disease, underwent peripheral blood stem cell transplantation and regained stable allograft function. Our study shows that kidney transplantation appears safe in patients with FGN with little risk of recurrence. However, patients with MGFD have a significant risk for disease recurrence. Whether the development of hematological malignancies following transplantation in this group is related to their original disease or was coincidental requires further studies.",
keywords = "Fibrillary, Gammopathy, Glomerulonephritis, Kidney, Monoclonal, Transplantation",
author = "Czarnecki, {Peter G.} and Lager, {Donna J.} and Nelson Leung and Angela Dispenzieri and Cosio, {Fernando G} and Fervenza, {Fernando Custodio}",
year = "2009",
month = "2",
doi = "10.1038/ki.2008.577",
language = "English (US)",
volume = "75",
pages = "420--427",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Long-term outcome of kidney transplantation in patients with fibrillary glomerulonephritis or monoclonal gammopathy with fibrillary deposits

AU - Czarnecki, Peter G.

AU - Lager, Donna J.

AU - Leung, Nelson

AU - Dispenzieri, Angela

AU - Cosio, Fernando G

AU - Fervenza, Fernando Custodio

PY - 2009/2

Y1 - 2009/2

N2 - To determine the outcome of kidney transplantation in patients with fibrillary glomerulonephritis (FGN), a rare glomerular disease, we followed 12 patients, 5 with FGN and 7 patients with monoclonal gammopathy and fibrillary deposits (MGFD), who underwent 15 kidney transplants since 1988 with a median follow-up of 52 months. Recurrent disease did not arise in any of the patients with FGN but developed in 5 patients with MGFD. Seven allografts failed: 1 in the FGN group and 6 in the MGFD group. Median allograft survival for patients with MGFD was 37 months but had not been reached in FGN patients. One patient with FGN had primary allograft failure secondary to graft thromboembolism. Three patients with MGFD were re-transplanted and one lost the second allograft to recurrent disease, but the other two died from hematological malignancy. Another patient was diagnosed with MPGN type III and did not have detectable fibrillary material 22 months after transplantation. One patient with MGFD had stable allograft function 6 months post-transplant but another, with recurrent disease, underwent peripheral blood stem cell transplantation and regained stable allograft function. Our study shows that kidney transplantation appears safe in patients with FGN with little risk of recurrence. However, patients with MGFD have a significant risk for disease recurrence. Whether the development of hematological malignancies following transplantation in this group is related to their original disease or was coincidental requires further studies.

AB - To determine the outcome of kidney transplantation in patients with fibrillary glomerulonephritis (FGN), a rare glomerular disease, we followed 12 patients, 5 with FGN and 7 patients with monoclonal gammopathy and fibrillary deposits (MGFD), who underwent 15 kidney transplants since 1988 with a median follow-up of 52 months. Recurrent disease did not arise in any of the patients with FGN but developed in 5 patients with MGFD. Seven allografts failed: 1 in the FGN group and 6 in the MGFD group. Median allograft survival for patients with MGFD was 37 months but had not been reached in FGN patients. One patient with FGN had primary allograft failure secondary to graft thromboembolism. Three patients with MGFD were re-transplanted and one lost the second allograft to recurrent disease, but the other two died from hematological malignancy. Another patient was diagnosed with MPGN type III and did not have detectable fibrillary material 22 months after transplantation. One patient with MGFD had stable allograft function 6 months post-transplant but another, with recurrent disease, underwent peripheral blood stem cell transplantation and regained stable allograft function. Our study shows that kidney transplantation appears safe in patients with FGN with little risk of recurrence. However, patients with MGFD have a significant risk for disease recurrence. Whether the development of hematological malignancies following transplantation in this group is related to their original disease or was coincidental requires further studies.

KW - Fibrillary

KW - Gammopathy

KW - Glomerulonephritis

KW - Kidney

KW - Monoclonal

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=59149084228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59149084228&partnerID=8YFLogxK

U2 - 10.1038/ki.2008.577

DO - 10.1038/ki.2008.577

M3 - Article

C2 - 19037251

AN - SCOPUS:59149084228

VL - 75

SP - 420

EP - 427

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 4

ER -